Sign in →

Mayo Test ID HK27M Histone H3 K27M Mutant (H3 K27M) Immunostain, Technical Component Only


Ordering Guidance


This test includes only technical performance of the stain (no pathologist interpretation is performed). If diagnostic consultation by a pathologist is required order PATHC / Pathology Consultation.

 

Mayo Clinic Laboratories has multiple histone immunostains available. See table for ordering guidance. 

Test ID

Published name

Indication

Mayo Clinic slide label

HG34W

Histone 3.3 G34W (H3F3A G34W) Immunostain, Technical Component Only

Giant cell tumor of bone (GCTB)

H3 G34W

HK27M

Histone H3 K27M Mutant (H3 K27M) Immunostain, Technical Component Only

K27M mutant midline gliomas

H3 K27M

HISME

Histone H3 Trimethyl K27 (H3 K27me[3]) Immunostain, Technical Component Only

MPNST and K27M mutant midline gliomas

H3 K27me3

HK36M

Histone H3 K36M Mutant (H3F3 K36M) Immunostain, Technical Component Only

Chondroblastoma

H3 K36M



Shipping Instructions


Attach the green "Attention Pathology" address label (T498) and the pink Immunostain Technical Only label included in the kit to the outside of the transport container.



Specimen Required


Supplies: Immunostain Technical Only Envelope (T693)

Specimen Type: Tissue

Container/Tube: Immunostain Technical Only Envelope

Preferred: 2 Unstained positively charged glass slide (25- x 75- x 1-mm) per test ordered; sections 4-microns thick.

Acceptable: Formalin-fixed, paraffin-embedded tissue block


Useful For

Identifying the presence of altered H3 K27M protein

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
IHTOI IHC Initial, Tech Only No No
IHTOA IHC Additional, Tech Only No No

Method Name

Immunohistochemistry (IHC)

Reporting Name

Histone H3 K27M IHC, Tech Only

Specimen Type

TECHONLY

Specimen Stability Information

Specimen Type Temperature Time Special Container
TECHONLY Ambient (preferred)
  Refrigerated 

Reject Due To

Wet/frozen tissue
Cytology smears
Nonformalin fixed tissue
Nonparaffin embedded tissue
Noncharged slides
ProbeOn slides
Reject

Clinical Information

Histone H3 K27M is an alteration in the H3F3A gene, encoding for histone H3.3. This alteration is characteristic of "diffuse midline glioma, H3 K27M-mutant," a new entity in the classification of central nervous system tumors, which carries a poor prognosis. H3 K27M-mutant diffuse midline glioma occurs most commonly in young children but, less frequently, can occur in adults. The most common locations include the brain stem, thalamus, and spinal cord. The term brain stem glioma and diffuse intrinsic pontine glioma were previously used to indicate tumors occurring in the brain stem and pons respectively.

Interpretation

This test does not include pathologist interpretation, only technical performance of the stain. If interpretation is required, order PATHC / Pathology Consultation for a full diagnostic evaluation or second opinion of the case.

 

The positive and negative controls are verified as showing appropriate immunoreactivity. If a control tissue is not included on the slide, a scanned image of the relevant quality control tissue is available upon request; call 855-516-8404.

 

Interpretation of this test should be performed in the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Cautions

Age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen dependent. Best practice is for paraffin sections to be cut within 6 weeks.

Clinical Reference

1. Venneti S, Santi M, Felicella MM, et al. A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas. Acta Neuropathol. 2014;128:743-753

2. Bechet D, Gielen GG, Korshunov A, et al. Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol. 2014;128:733-741

3. Korshunov A, Ryzhova M, Hovestadt V, et al. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol. 2015;129:669-678

4. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodeling genes in paediatric glioblastoma. Nature. 2012;482:226-231

5. Magaki S, Hojat SA, Wei B, So A, Yong WH. An introduction to the performance of immunohistochemistry. Methods Mol Biol. 2019;1897:289-298. doi:10.1007/978-1-4939-8935-5_25

Method Description

Immunohistochemistry on sections of paraffin-embedded tissue.(Unpublished Mayo method)

Day(s) Performed

Monday through Friday

Report Available

1 to 3 days

Specimen Retention Time

Until staining is complete.

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

88342-TC, primary

88341-TC, if additional IHC

LOINC Code Information

Test ID Test Order Name Order LOINC Value
HK27M Histone H3 K27M IHC, Tech Only Order only;no result

 

Result ID Test Result Name Result LOINC Value
604990 Histone H3 K27M IHC, Tech Only Bill only; no result

Testing Algorithm

For the initial technical component only immunohistochemical (IHC) stain performed, the appropriate bill-only test ID will be reflexed and charged (IHTOI). For each additional technical component only IHC stain performed, an additional bill-only test ID will be reflexed and charged (IHTOA).